KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBIT: 2019-2024

Historic EBIT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$479.0 million.

  • Recursion Pharmaceuticals' EBIT fell 75.08% to -$172.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$723.6 million, marking a year-over-year decrease of 83.57%. This contributed to the annual value of -$479.0 million for FY2024, which is 36.83% down from last year.
  • As of FY2024, Recursion Pharmaceuticals' EBIT stood at -$479.0 million, which was down 36.83% from -$350.1 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' EBIT registered a high of -$84.6 million during FY2020, and its lowest value of -$479.0 million during FY2024.
  • For the 3-year period, Recursion Pharmaceuticals' EBIT averaged around -$358.3 million, with its median value being -$350.1 million (2023).
  • Data for Recursion Pharmaceuticals' EBIT shows a maximum YoY crashed of 116.01% (in 2021) over the last 5 years.
  • Over the past 5 years, Recursion Pharmaceuticals' EBIT (Yearly) stood at -$84.6 million in 2020, then plummeted by 116.01% to -$182.8 million in 2021, then slumped by 34.44% to -$245.7 million in 2022, then tumbled by 42.46% to -$350.1 million in 2023, then crashed by 36.83% to -$479.0 million in 2024.